Cerus CE marks Intercept for frozen plasma
This article was originally published in Clinica
Executive Summary
Concord, California company Cerus has CE marked its Intercept blood system, allowing its sale in Europe to purify previously frozen plasma. Intercept is designed to reduce the risk of diseases being transmitted in contaminated blood by inactivating a broad range of viral, bacterial and parasitic pathogens, as well as harmful white blood cells that may be present in donated blood. The expanded claim means that blood banks in countries that recognise the CE mark may now use Intercept to purify either previously frozen or freshly collected plasma. This will help to permit the use of imported plasma and plasma in quarantined inventory, both of which are previously frozen. Cerus CE marked the Intercept system for platelets in 2002 and for fresh plasma in 2006 (see Clinica No 1236, p 22).
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.